Robert Zeldin
Chief Tech/Sci/R&D Officer chez MEIRAGTX HOLDINGS PLC
Fortune : 544 625 $ au 31/03/2024
Profil
Robert K.
Zeldin is currently the Chief Medical Officer at MeiraGTx Holdings Plc.
Prior to this, he worked as the Chief Medical Officer & Executive Vice President at Acceleron Pharma, Inc. from 2018 to 2019, and as the Senior Vice President-Global Clinical Development at Stallergenes SA from 2011 to 2015.
He also held positions as Chief Medical Officer at Ablynx NV, Vice President at Novartis Pharmaceuticals Corp., Medical Officer at the Center for Biologics Evaluation & Research, and Chief Medical Officer at Immunovant, Inc. Zeldin received his undergraduate degree from The Johns Hopkins University and his doctorate from Tufts University School of Medicine.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
MEIRAGTX HOLDINGS PLC
0,14% | 17/01/2024 | 89 724 ( 0,14% ) | 544 625 $ | 31/03/2024 |
Postes actifs de Robert Zeldin
Sociétés | Poste | Début |
---|---|---|
MEIRAGTX HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 05/08/2020 |
Anciens postes connus de Robert Zeldin
Sociétés | Poste | Fin |
---|---|---|
ACCELERON PHARMA INC. | Chief Tech/Sci/R&D Officer | 05/04/2019 |
STALLERGENES | Chief Tech/Sci/R&D Officer | 01/01/2015 |
IMMUNOVANT, INC. | Chief Tech/Sci/R&D Officer | - |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Center for Biologics Evaluation & Research
Center for Biologics Evaluation & Research Miscellaneous Commercial ServicesCommercial Services Center for Biologics Evaluation & Research engages in the regulation of biological and related products. Its scope includes blood, vaccines, allergenics, tissues, and cellular and gene therapies. The company is headquartered in Silver Spring, MD. | Chief Tech/Sci/R&D Officer | - |
Formation de Robert Zeldin
The Johns Hopkins University | Undergraduate Degree |
Tufts University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
MEIRAGTX HOLDINGS PLC | Health Technology |
IMMUNOVANT, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Stallergenes SA
Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Center for Biologics Evaluation & Research
Center for Biologics Evaluation & Research Miscellaneous Commercial ServicesCommercial Services Center for Biologics Evaluation & Research engages in the regulation of biological and related products. Its scope includes blood, vaccines, allergenics, tissues, and cellular and gene therapies. The company is headquartered in Silver Spring, MD. | Commercial Services |